SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending sharply lower after announcing that Marvell canceled all purchase orders inherited from its acquisition of Celestial AI due to an alleged breach of confidentiality. Investors and community members are expressing significant frustration over management's handling of the disclosure, leading to widespread speculation about the company's future contracts and immediate valuation.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as they await topline Phase 3 data from the HAELO trial, which the community sees as a potential validation for their in vivo CRISPR platform. Traders are actively debating the high short interest and the stock's susceptibility to a squeeze, with many weighing the clinical promise of a functional HAE cure against the broader volatility affecting the biotech sector.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors weigh strong AI and automotive growth potential against near-term headwinds like supply chain constraints and cautious analyst sentiment. The stock is a primary focus for the community, which remains divided on whether the current price represents a buying opportunity or a deeper structural decline.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is experiencing significant bullish momentum driven by heavy short interest and mounting anticipation for its acquisition of Northern Data, which effectively expands its cloud and GPU infrastructure. The community is actively discussing a potential short squeeze, citing record-high short interest and strong backing from strategic partner Tether as catalysts for a potential rally.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing significant market movement driven by speculative interest in its shift toward custom AI chip design and high-performance server CPUs. Community discussions are split between euphoria over its long-term potential as an AI infrastructure backbone and intense debate regarding its valuation, with many traders actively debating the merits of aggressive shorting versus holding for a potential parabolic breakout.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is attracting intense investor interest as the company prepares for an oral presentation of its pancreatic cancer data at the upcoming Digestive Disease Week conference. The community is buzzing with anticipation over a strong pipeline of clinical catalysts, with many retail traders actively accumulating shares in expectation of a significant breakout.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares is experiencing massive volatility and bullish momentum driven by a strong semiconductor sector rally, fueled by earnings optimism and ongoing AI infrastructure spending. Investors are actively debating whether the current parabolic price action signifies a sustainable super-cycle or a speculative bubble, leading to intense sentiment clashes between bullish 'diamond hands' and traders betting on a sharp mean reversion.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing intense volatility and record-breaking volume as traders debate whether the semiconductor sector's prolonged winning streak represents an unsustainable AI bubble or a resilient super-cycle. Community sentiment remains deeply polarized between aggressive short-sellers betting on a mean reversion and bulls who argue that relentless momentum and capital rotation into chip-related infrastructure make shorting the sector a high-risk trade.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently seeing significant investor attention driven by positive Phase 3 acne data and the potential for its FASN inhibitor denifanstat as a cornerstone MASH treatment. The community is actively debating the company's valuation, the strategic shift toward combination therapies, and the high probability of a future buyout given the surge in M&A activity within the metabolic disease sector.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as retail and institutional investors capitalize on its pivot into high-margin custom AI silicon and optical connectivity, with community discourse centered on potential hyperscaler partnerships and structural demand for its networking infrastructure. Traders are closely monitoring the stock's parabolic ascent, fueled by reports of custom chip collaborations and significant options flow, as the community debates whether the momentum represents an infrastructure-led re-rating or a classic overextended squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class...

Wall Street Zen Upgrades Prima BioMed (NASDAQ:IMMP) to Hold

Wall Street Zen upgraded Prima BioMed to a "hold" rating in a report on Saturday...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep...

Prima BioMed Sees Unusually Large Options Volume (NASDAQ:IMMP)

Prima BioMed Ltd (NASDAQ:IMMP - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 8,815 call options on the company. This represents an increase...

From Sneakers to AI Powerhouse

Today’s tape includes microcap breakouts, biotech catalysts, and radical corporate reinventions colliding in a market that’s increasingly rewarding narrative velocity over legacy stability. $IMMP, $TGNT, $AGAE, $BIRD, $VSA, $CIIT, $LRHC, $NNBR, $SNAP

IMMP Investor Alert: Immutep Ltd. Securities Fraud Investigation - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Material Risks Related To Trial Viability : Levi & Korsinsky

IMMP Investor Alert: Immutep Ltd. Securities Fraud Investigation - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Material Risks Related To Trial...

<ul class="summary-bullets"><li>The FDA issues ODD to therapies showing encouraging results for treating diseases affecting fewer than 200,000 people.</li><li>This comes after a successful trial of the company’s Eftilagimod Alfa, tested with radiotherapy and the immunotherapy drug Keytruda in patients before surgery.</li><li>Last month, a trial for Efti in first-line non-small cell lung cancer was stopped, leading to an 82% intraday plunge in IMMP stock.</li></ul>Shares of Immutep Ltd (IMMP) surged around 150% in pre-market trading on Wednesday, on track for their biggest intraday gains since Dec. 10, 2020, after the biotech firm announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for its drug to treat soft tissue sarcoma.The decision is supported by encouraging results from the Phase II EFTISARC-NEO trial, in which Eftilagimod Alfa (Efti) was tested with radiotherapy and the immunotherapy drug Keytruda in patients before surgery. In 38 patients, the study met its primary endpoint, showing a median tumor hyalinization/fibrosis of 51.5%, well above the 35% target. This essentially means that half of the tumor tissue showed signs of being replaced by scar-like tissue.The FDA issues ODD to therapies showing encouraging results for treating diseases affecting fewer than 200,000 people. The designation comes with additional benefits, including regulatory assistance, tax credits, fee waivers, and 7 years of market exclusivity upon approval.<h2 class="st-heading-2">Silver Lining After Phase III TACTI-004 Trial Was Abandoned</h2>In March, Immutep announced that its Phase III TACTI-004 trial of Efti in first-line non-small cell lung cancer will be stopped following an interim review by the Independent Data Monitoring Committee (IDMC), which found that the study was unlikely to meet its goals. Following this decision, Immutep expects its cash runway to extend beyond its earlier guidance of the second quarter (Q2) of 2027.The stock plunged 82% after the March 13 update, dropping below $1 and failing to recover since then. Prior to the update, IMMP shares were placed under a trading halt for five sessions.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on <a href="https://stocktwits.com/symbol/IMMP">IMMP stock</a> flipped to ‘extremely bullish’ from ‘bearish’ a day earlier.One user expects the latest news to lead to new partnerships or even an acquisition.&nbsp;<stembedurl>https://stocktwits.com/joe77w/message/650314490</stembedurl>However, another user said that the Phase III TACTI-004 failure “still defines the long-term trend.”<stembedurl>https://stocktwits.com/Treasuremovers/message/650314616</stembedurl>The stock has crashed around 80% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

Why Did IMMP Stock Surge 150% In Pre-Market Today?

Immutep announced that the U.S. FDA granted Orphan Drug Designation for its drug for the treatment of soft-tissue sarcoma.

Why Is This Beaten-Down Biotech Surging 150% In Pre-Market Today?

Equity

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP PR Newswire NEW YORK, April 2, 2026 NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP...

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

IMMP
Immutep LTD ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IMMP News

IMMPImmutep LTD ADR